Evidence map›Paper›PMID 30462147›Full record

ArticleBioinformatics (Oxford, England)2019

Application of machine learning techniques to tuberculosis drug resistance analysis.

Samaneh Kouchaki, Yang Yang, Timothy M Walker, A Sarah Walker, Daniel J Wilson, Timothy E A Peto, Derrick W Crook, CRyPTIC Consortium, David A Clifton

Open access · hybridAbstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 108 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Predicting rifampicin resistance inERJ open research · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Predicting antimicrobial resistance inComputational and structural biotechnology journal · 2024
    Article
  16. Article
  17. Prediction of pyrazinamide resistance inJAC-antimicrobial resistance · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Samaneh KouchakiDepartment of Engineering Science, Institute of Biomedical Engineering.
Yang YangDepartment of Engineering Science, Institute of Biomedical Engineering.
Timothy M WalkerNuffield Department of Medicine, University of Oxford.
A Sarah WalkerNuffield Department of Medicine, University of Oxford.
Daniel J WilsonNuffield Department of Population Health, Big Data Institute, University of Oxford, Li Ka Shing Centre for Health Information and Discovery, Oxford, UK.
Timothy E A PetoNuffield Department of Medicine, University of Oxford.
Derrick W CrookNuffield Department of Medicine, University of Oxford.
CRyPTIC Consortium
David A CliftonDepartment of Engineering Science, Institute of Biomedical Engineering.
John Radcliffe Hospital · GBHealth Data Research UK · GBMedical Research Council · GBUniversity of Oxford · GB

Funding

Department of HealthMedical Research Council MC_PC_16027Wellcome TrustWellcome Trust 101237/Z/13/ZWellcome Trust 200205/Z/15/Z
6 · The paper itself

Abstract

motivationTimely identification of Mycobacterium tuberculosis (MTB) resistance to existing drugs is vital to decrease mortality and prevent the amplification of existing antibiotic resistance. Machine learning methods have been widely applied for timely predicting resistance of MTB given a specific drug and identifying resistance markers. However, they have been not validated on a large cohort of MTB samples from multi-centers across the world in terms of resistance prediction and resistance marker identification. Several machine learning classifiers and linear dimension reduction techniques were developed and compared for a cohort of 13 402 isolates collected from 16 countries across 6 continents and tested 11 drugs.

resultsCompared to conventional molecular diagnostic test, area under curve of the best machine learning classifier increased for all drugs especially by 23.11%, 15.22% and 10.14% for pyrazinamide, ciprofloxacin and ofloxacin, respectively (P < 0.01). Logistic regression and gradient tree boosting found to perform better than other techniques. Moreover, logistic regression/gradient tree boosting with a sparse principal component analysis/non-negative matrix factorization step compared with the classifier alone enhanced the best performance in terms of F1-score by 12.54%, 4.61%, 7.45% and 9.58% for amikacin, moxifloxacin, ofloxacin and capreomycin, respectively, as well increasing area under curve for amikacin and capreomycin. Results provided a comprehensive comparison of various techniques and confirmed the application of machine learning for better prediction of the large diverse tuberculosis data. Furthermore, mutation ranking showed the possibility of finding new resistance/susceptible markers. AVAILABILITY AND IMPLEMENTATION: The source code can be found at http://www.robots.ox.ac.uk/ davidc/code.php. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Indexed as

Mycobacterium tuberculosisTuberculosisAntitubercular AgentsHumansMachine LearningAntitubercular Agents

Identifiers

PMID30462147
PMCPMC6596891
OpenAlexW2901155787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.